Amivantamab, sold under the brand name Rybrevant, is a bispecific monoclonal antibody used to treat non-small cell lung cancer. Amivantamab is a bispecific...
23 KB (1,757 words) - 06:04, 16 July 2024
treatment of relapsing remitting multiple sclerosis (Novartis) Rybrevant (amivantamab) for the treatment of non-small-cell lung cancer (EGFR exon 20 insertion...
26 KB (1,906 words) - 04:10, 19 June 2024
drugs have since been approved by the US FDA: blinatumomab, emacizumab, amivantamab, tebentafusp, faricimab, teclistamab, mosunetuzumab, epcoritamab, glofitamab...
29 KB (3,349 words) - 19:04, 30 July 2024
mafodotin L01FX16 Oportuzumab monatox L01FX17 Sacituzumab govitecan L01FX18 Amivantamab L01FX19 Sabatolimab L01FX20 Tremelimumab L01FX21 Naxitamab L01FX22 Loncastuximab...
12 KB (877 words) - 15:36, 25 January 2024
disease Bupivacaine/meloxicam Heron Therapeutics postsurgical analgesia Amivantamab Janssen Biotech non-small cell lung cancer with EGFR exon 20 insertion...
34 KB (180 words) - 22:09, 8 April 2024
colorectal cancer (diagnosis) Amatuximab mab chimeric mesothelin cancer Amivantamab Rybrevant BsAb human Epidermal growth factor receptor (EGFR), cMet Y...
135 KB (4,054 words) - 22:35, 2 July 2024
(Brentuximab), CD52 (Alemtuzumab) myeloid: CD33 (Gemtuzumab ozogamicin) Other Amivantamab Atezolizumab Avelumab Belantamab mafodotin Bermekimab Blinatumomab Cemiplimab...
12 KB (760 words) - 03:40, 23 July 2024
(Brentuximab), CD52 (Alemtuzumab) myeloid: CD33 (Gemtuzumab ozogamicin) Other Amivantamab Atezolizumab Avelumab Belantamab mafodotin Bermekimab Blinatumomab Cemiplimab...
12 KB (758 words) - 23:46, 14 March 2024
Human Adecatumumab§ Amivantamab Ascrinvacumab§ Atezolizumab Balstilimab† Botensilimab Cixutumumab§ Conatumumab§ Daratumumab Drozitumab§ Duligotumab§ Dusigitumab§...
5 KB (368 words) - 23:51, 17 July 2024
Human Adecatumumab§ Amivantamab Ascrinvacumab§ Atezolizumab Balstilimab† Botensilimab Cixutumumab§ Conatumumab§ Daratumumab Drozitumab§ Duligotumab§ Dusigitumab§...
3 KB (129 words) - 01:04, 19 July 2023
at least one other prior line of therapy. In 2021, the FDA approved amivantamab as the first treatment for patients with metastatic non-small cell lung...
59 KB (6,487 words) - 18:42, 27 December 2023
Human Adecatumumab§ Amivantamab Ascrinvacumab§ Atezolizumab Balstilimab† Botensilimab Cixutumumab§ Conatumumab§ Daratumumab Drozitumab§ Duligotumab§ Dusigitumab§...
4 KB (241 words) - 13:42, 14 July 2024